Abhyanga with Mahanarayana taila as an add on to the standard of care in chemotherapy induced peripheral neuropathy: a non-randomized clinical control trial - NI

Dr Namboodiri Aiswarya Raman0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1)Neuropathy attributed to chemotherapeutic agents with no prior history of attributable cause for chemotherapy induced peripheral neuropathy.
•2)Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 3.
•3)Self-reported neuropathy score greater than or equal to 3 on 0-10 scale and/or grade 2 or 3 neuropathy according to NCI-CTCAEv5 criteria.
•4)Life expectancy more than 3 months.
•5)Those who are willing to participate in this study and sign informed consent forms.

•1)Peripheral neuropathy other than those induced by neurotoxic chemotherapeutic agents.
•2)Abnormal cognition and speech - causing difficulty in comprehension, expression and signing informed consent
•3)Age below 18 and above 60 years.
•4)Pregnancy, lactating mothers.

发起方

Dr Namboodiri Aiswarya Raman